International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease

The Global Pneumococcal Sequencing Consortium; R. A. Gladstone; L. Siira; O. B. Brynildsrud; D. F. Vestrheim; P. Turner; S. C. Clarke; S. Srifuengfung; R. Ford; D. Lehmann; E. Egorova; E. Voropaeva; G. Haraldsson; K. G. Kristinsson; L. McGee; R. F. Breiman; S. D. Bentley; C. L. Sheppard; N. K. Fry; J. Corander; M. Toropainen; A. Steens

doi:10.1016/j.vaccine.2021.10.046

International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease

The Global Pneumococcal Sequencing Consortium, R. A. Gladstone, L. Siira, O. B. Brynildsrud, D. F. Vestrheim, P. Turner, S. C. Clarke, S. Srifuengfung, R. Ford, D. Lehmann, E. Egorova, E. Voropaeva, G. Haraldsson, K. G. Kristinsson, L. McGee, R. F. Breiman, S. D. Bentley, C. L. Sheppard, N. K. Fry, J. CoranderM. Toropainen, A. Steens

Immunisation Hepatitis and Blood Safety

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

17 Downloads (Pure)

Abstract

Background: Pneumococcal disease outbreaks of vaccine preventable serotype 4 sequence type (ST)801 in shipyards have been reported in several countries. We aimed to use genomics to establish any international links between them.

Methods: Sequence data from ST801-related outbreak isolates from Norway (n = 17), Finland (n = 11) and Northern Ireland (n = 2) were combined with invasive pneumococcal disease surveillance from the respective countries, and ST801-related genomes from an international collection (n = 41 of > 40,000), totalling 106 genomes. Raw data were mapped and recombination excluded before phylogenetic dating.

Results: Outbreak isolates were relatively diverse, with up to 100 SNPs (single nucleotide polymorphisms) and a common ancestor estimated around the year 2000. However, 19 Norwegian and Finnish isolates were nearly indistinguishable (0–2 SNPs) with the common ancestor dated around 2017.

Conclusion: The total diversity of ST801 within the outbreaks could not be explained by recent transmission alone, suggesting that harsh environmental and associated living conditions reported in the shipyards may facilitate invasion of colonising pneumococci. However, near identical strains in the Norwegian and Finnish outbreaks does suggest that transmission between international shipyards also contributed to those outbreaks. This indicates the need for improved preventative measures in this working population including pneumococcal vaccination.

Original language	English
Pages (from-to)	1054-1060
Number of pages	7
Journal	Vaccine
Volume	40
Issue number	7
Early online date	5 Jan 2022
DOIs	https://doi.org/10.1016/j.vaccine.2021.10.046
Publication status	Published - 11 Feb 2022

Bibliographical note

Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing
interests: [R.A.G received a PhD stipend from Pfizer 2009–2011. L.S is a co-investigator in an unrelated study, for which THL has received research funding from GlaxoSmithKline Vaccines. S.C.C: acts as principal investigator on studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/University of Southampton that are sponsored by vaccine manufacturers but
receives no personal payments from them. S.C.C. has participated in advisory boards for vaccine manufacturers but receives no personal payments for this work. S.C.C. has received financial assistance from vaccine manufacturers to attend conferences. All grants and honoraria are paid into accounts within the respective NHS Trusts or Universities, or to independent charities. N.K.F, C.L.S
The Immunisation and Countermeasures Division, Public Health England - National Infection Service, London, UK provides vaccine manufacturers with post-marketing surveillance reports, which the Marketing Authorization Holders are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. N.K.F and C.S. conduct contract research funded by vaccine manufacturers (including GlaxoSmithKline and Pfizer) on behalf of Public Health England. No personal remuneration is received. M.T reports grants from GlaxoSmithKline and Pfizer to the Finnish Institute for Health and Welfare for unrelated research projects in which she is a co-investigator. All remaining authors report no conflicts of
interest.]

Sequencing of outbreak and contemporary IPD surveillance isolates were funded internally in the respective public health institutes. The Global Pneumococcal Sequencing project was funded by Wellcome Trust, grant number 206194/Z/17/Z, and by the Bill and Melinda Gates Foundation, Investment ID INV-003570. J.C. was funded by the European Research Council grant no. 742158.PT is funded by the Wellcome Trust (Thailand-Laos AAP core award, grant no. 220211).

Publisher Copyright: © 2021 The Author(s). Published by Elsevier Ltd.

Citation: Gladstone, R. A., et al. "International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease." Vaccine (2022).

DOI: https://doi.org/10.1016/j.vaccine.2021.10.046

Keywords

Molecular epidemiology
Outbreak
PCVs
PPV23
Pneumococcal
ST801
Serotype 4
Streptococcus pneumoniae
Whole genome sequencing
RISK
WELDERS
EPIDEMIOLOGY

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2021.10.046Licence: CC BY

Gladstone2022InternationalLinksBetweenStreptococcusPneumoniaeVaccineSerotypeVaccineFinal published version, 510 KBLicence: CC BY

Cite this

The Global Pneumococcal Sequencing Consortium, Gladstone, R. A., Siira, L., Brynildsrud, O. B., Vestrheim, D. F., Turner, P., Clarke, S. C., Srifuengfung, S., Ford, R., Lehmann, D., Egorova, E., Voropaeva, E., Haraldsson, G., Kristinsson, K. G., McGee, L., Breiman, R. F., Bentley, S. D., Sheppard, C. L., Fry, N. K., ... Steens, A. (2022). International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease. Vaccine, 40(7), 1054-1060. https://doi.org/10.1016/j.vaccine.2021.10.046

@article{c8e5af6025e144c89e84f364fe0a647d,

title = "International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease",

abstract = "Background: Pneumococcal disease outbreaks of vaccine preventable serotype 4 sequence type (ST)801 in shipyards have been reported in several countries. We aimed to use genomics to establish any international links between them. Methods: Sequence data from ST801-related outbreak isolates from Norway (n = 17), Finland (n = 11) and Northern Ireland (n = 2) were combined with invasive pneumococcal disease surveillance from the respective countries, and ST801-related genomes from an international collection (n = 41 of > 40,000), totalling 106 genomes. Raw data were mapped and recombination excluded before phylogenetic dating. Results: Outbreak isolates were relatively diverse, with up to 100 SNPs (single nucleotide polymorphisms) and a common ancestor estimated around the year 2000. However, 19 Norwegian and Finnish isolates were nearly indistinguishable (0–2 SNPs) with the common ancestor dated around 2017. Conclusion: The total diversity of ST801 within the outbreaks could not be explained by recent transmission alone, suggesting that harsh environmental and associated living conditions reported in the shipyards may facilitate invasion of colonising pneumococci. However, near identical strains in the Norwegian and Finnish outbreaks does suggest that transmission between international shipyards also contributed to those outbreaks. This indicates the need for improved preventative measures in this working population including pneumococcal vaccination.",

keywords = "Molecular epidemiology, Outbreak, PCVs, PPV23, Pneumococcal, ST801, Serotype 4, Streptococcus pneumoniae, Whole genome sequencing, RISK, WELDERS, EPIDEMIOLOGY",

author = "{The Global Pneumococcal Sequencing Consortium} and Gladstone, {R. A.} and L. Siira and Brynildsrud, {O. B.} and Vestrheim, {D. F.} and P. Turner and Clarke, {S. C.} and S. Srifuengfung and R. Ford and D. Lehmann and E. Egorova and E. Voropaeva and G. Haraldsson and Kristinsson, {K. G.} and L. McGee and Breiman, {R. F.} and Bentley, {S. D.} and Sheppard, {C. L.} and Fry, {N. K.} and J. Corander and M. Toropainen and A. Steens and Akpaka, {Patrick E.} and Krow Ampofo and Martin Antonio and Veeraraghavan Balaji and Beall, {Bernard W.} and Houria Belabb{\`e}s and Rachel Benisty and Bentley, {Stephen D.} and Godfrey Bigogo and Breiman, {Robert F.} and Brooks, {Abdullah W.} and Carter, {Philip E.} and Clarke, {Stuart C.} and Cornick, {Jennifer E.} and Alejandra Corso and {Cristina de Cunto Brandileone}, Maria and {Cristine Grassi Almeida}, Samanta and Croucher, {Nicholas J.} and Ron Dagan and Alexander Davydov and Idrissa Diawara and Sanjay Doiphode and {du Plessis}, Mignon and Ekaterina Egorova and Naima Elmdaghri and {K{\"o}seoglu Eser}, {\"O}zgen and Everett, {Dean B.} and Diego Faccone and Rebecca Ford",

note = "Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [R.A.G received a PhD stipend from Pfizer 2009–2011. L.S is a co-investigator in an unrelated study, for which THL has received research funding from GlaxoSmithKline Vaccines. S.C.C: acts as principal investigator on studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/University of Southampton that are sponsored by vaccine manufacturers but receives no personal payments from them. S.C.C. has participated in advisory boards for vaccine manufacturers but receives no personal payments for this work. S.C.C. has received financial assistance from vaccine manufacturers to attend conferences. All grants and honoraria are paid into accounts within the respective NHS Trusts or Universities, or to independent charities. N.K.F, C.L.S The Immunisation and Countermeasures Division, Public Health England - National Infection Service, London, UK provides vaccine manufacturers with post-marketing surveillance reports, which the Marketing Authorization Holders are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. N.K.F and C.S. conduct contract research funded by vaccine manufacturers (including GlaxoSmithKline and Pfizer) on behalf of Public Health England. No personal remuneration is received. M.T reports grants from GlaxoSmithKline and Pfizer to the Finnish Institute for Health and Welfare for unrelated research projects in which she is a co-investigator. All remaining authors report no conflicts of interest.] Sequencing of outbreak and contemporary IPD surveillance isolates were funded internally in the respective public health institutes. The Global Pneumococcal Sequencing project was funded by Wellcome Trust, grant number 206194/Z/17/Z, and by the Bill and Melinda Gates Foundation, Investment ID INV-003570. J.C. was funded by the European Research Council grant no. 742158.PT is funded by the Wellcome Trust (Thailand-Laos AAP core award, grant no. 220211). Publisher Copyright: {\textcopyright} 2021 The Author(s). Published by Elsevier Ltd. Citation: Gladstone, R. A., et al. {"}International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease.{"} Vaccine (2022). DOI: https://doi.org/10.1016/j.vaccine.2021.10.046",

year = "2022",

month = feb,

day = "11",

doi = "10.1016/j.vaccine.2021.10.046",

language = "English",

volume = "40",

pages = "1054--1060",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "7",

}

The Global Pneumococcal Sequencing Consortium, Gladstone, RA, Siira, L, Brynildsrud, OB, Vestrheim, DF, Turner, P, Clarke, SC, Srifuengfung, S, Ford, R, Lehmann, D, Egorova, E, Voropaeva, E, Haraldsson, G, Kristinsson, KG, McGee, L, Breiman, RF, Bentley, SD, Sheppard, CL, Fry, NK, Corander, J, Toropainen, M & Steens, A 2022, 'International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease', Vaccine, vol. 40, no. 7, pp. 1054-1060. https://doi.org/10.1016/j.vaccine.2021.10.046

International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease. / The Global Pneumococcal Sequencing Consortium; Gladstone, R. A.; Siira, L. et al.
In: Vaccine, Vol. 40, No. 7, 11.02.2022, p. 1054-1060.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease

AU - The Global Pneumococcal Sequencing Consortium

AU - Gladstone, R. A.

AU - Siira, L.

AU - Brynildsrud, O. B.

AU - Vestrheim, D. F.

AU - Turner, P.

AU - Clarke, S. C.

AU - Srifuengfung, S.

AU - Ford, R.

AU - Lehmann, D.

AU - Egorova, E.

AU - Voropaeva, E.

AU - Haraldsson, G.

AU - Kristinsson, K. G.

AU - McGee, L.

AU - Breiman, R. F.

AU - Bentley, S. D.

AU - Sheppard, C. L.

AU - Fry, N. K.

AU - Corander, J.

AU - Toropainen, M.

AU - Steens, A.

AU - Akpaka, Patrick E.

AU - Ampofo, Krow

AU - Antonio, Martin

AU - Balaji, Veeraraghavan

AU - Beall, Bernard W.

AU - Belabbès, Houria

AU - Benisty, Rachel

AU - Bentley, Stephen D.

AU - Bigogo, Godfrey

AU - Breiman, Robert F.

AU - Brooks, Abdullah W.

AU - Carter, Philip E.

AU - Clarke, Stuart C.

AU - Cornick, Jennifer E.

AU - Corso, Alejandra

AU - Cristina de Cunto Brandileone, Maria

AU - Cristine Grassi Almeida, Samanta

AU - Croucher, Nicholas J.

AU - Dagan, Ron

AU - Davydov, Alexander

AU - Diawara, Idrissa

AU - Doiphode, Sanjay

AU - du Plessis, Mignon

AU - Egorova, Ekaterina

AU - Elmdaghri, Naima

AU - Köseoglu Eser, Özgen

AU - Everett, Dean B.

AU - Faccone, Diego

AU - Ford, Rebecca

N1 - Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [R.A.G received a PhD stipend from Pfizer 2009–2011. L.S is a co-investigator in an unrelated study, for which THL has received research funding from GlaxoSmithKline Vaccines. S.C.C: acts as principal investigator on studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/University of Southampton that are sponsored by vaccine manufacturers but receives no personal payments from them. S.C.C. has participated in advisory boards for vaccine manufacturers but receives no personal payments for this work. S.C.C. has received financial assistance from vaccine manufacturers to attend conferences. All grants and honoraria are paid into accounts within the respective NHS Trusts or Universities, or to independent charities. N.K.F, C.L.S The Immunisation and Countermeasures Division, Public Health England - National Infection Service, London, UK provides vaccine manufacturers with post-marketing surveillance reports, which the Marketing Authorization Holders are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. N.K.F and C.S. conduct contract research funded by vaccine manufacturers (including GlaxoSmithKline and Pfizer) on behalf of Public Health England. No personal remuneration is received. M.T reports grants from GlaxoSmithKline and Pfizer to the Finnish Institute for Health and Welfare for unrelated research projects in which she is a co-investigator. All remaining authors report no conflicts of interest.] Sequencing of outbreak and contemporary IPD surveillance isolates were funded internally in the respective public health institutes. The Global Pneumococcal Sequencing project was funded by Wellcome Trust, grant number 206194/Z/17/Z, and by the Bill and Melinda Gates Foundation, Investment ID INV-003570. J.C. was funded by the European Research Council grant no. 742158.PT is funded by the Wellcome Trust (Thailand-Laos AAP core award, grant no. 220211). Publisher Copyright: © 2021 The Author(s). Published by Elsevier Ltd. Citation: Gladstone, R. A., et al. "International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease." Vaccine (2022). DOI: https://doi.org/10.1016/j.vaccine.2021.10.046

PY - 2022/2/11

Y1 - 2022/2/11

N2 - Background: Pneumococcal disease outbreaks of vaccine preventable serotype 4 sequence type (ST)801 in shipyards have been reported in several countries. We aimed to use genomics to establish any international links between them. Methods: Sequence data from ST801-related outbreak isolates from Norway (n = 17), Finland (n = 11) and Northern Ireland (n = 2) were combined with invasive pneumococcal disease surveillance from the respective countries, and ST801-related genomes from an international collection (n = 41 of > 40,000), totalling 106 genomes. Raw data were mapped and recombination excluded before phylogenetic dating. Results: Outbreak isolates were relatively diverse, with up to 100 SNPs (single nucleotide polymorphisms) and a common ancestor estimated around the year 2000. However, 19 Norwegian and Finnish isolates were nearly indistinguishable (0–2 SNPs) with the common ancestor dated around 2017. Conclusion: The total diversity of ST801 within the outbreaks could not be explained by recent transmission alone, suggesting that harsh environmental and associated living conditions reported in the shipyards may facilitate invasion of colonising pneumococci. However, near identical strains in the Norwegian and Finnish outbreaks does suggest that transmission between international shipyards also contributed to those outbreaks. This indicates the need for improved preventative measures in this working population including pneumococcal vaccination.

AB - Background: Pneumococcal disease outbreaks of vaccine preventable serotype 4 sequence type (ST)801 in shipyards have been reported in several countries. We aimed to use genomics to establish any international links between them. Methods: Sequence data from ST801-related outbreak isolates from Norway (n = 17), Finland (n = 11) and Northern Ireland (n = 2) were combined with invasive pneumococcal disease surveillance from the respective countries, and ST801-related genomes from an international collection (n = 41 of > 40,000), totalling 106 genomes. Raw data were mapped and recombination excluded before phylogenetic dating. Results: Outbreak isolates were relatively diverse, with up to 100 SNPs (single nucleotide polymorphisms) and a common ancestor estimated around the year 2000. However, 19 Norwegian and Finnish isolates were nearly indistinguishable (0–2 SNPs) with the common ancestor dated around 2017. Conclusion: The total diversity of ST801 within the outbreaks could not be explained by recent transmission alone, suggesting that harsh environmental and associated living conditions reported in the shipyards may facilitate invasion of colonising pneumococci. However, near identical strains in the Norwegian and Finnish outbreaks does suggest that transmission between international shipyards also contributed to those outbreaks. This indicates the need for improved preventative measures in this working population including pneumococcal vaccination.

KW - Molecular epidemiology

KW - Outbreak

KW - PCVs

KW - PPV23

KW - Pneumococcal

KW - ST801

KW - Serotype 4

KW - Streptococcus pneumoniae

KW - Whole genome sequencing

KW - RISK

KW - WELDERS

KW - EPIDEMIOLOGY

UR - http://www.scopus.com/inward/record.url?scp=85122325554&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2021.10.046

DO - 10.1016/j.vaccine.2021.10.046

M3 - Article

AN - SCOPUS:85122325554

SN - 0264-410X

VL - 40

SP - 1054

EP - 1060

JO - Vaccine

JF - Vaccine

IS - 7

ER -

The Global Pneumococcal Sequencing Consortium, Gladstone RA, Siira L, Brynildsrud OB, Vestrheim DF, Turner P et al. International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease. Vaccine. 2022 Feb 11;40(7):1054-1060. Epub 2022 Jan 5. doi: 10.1016/j.vaccine.2021.10.046

International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this